This article first appeared on GuruFocus .
Release Date: November 12, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Cohance Lifesciences Ltd ( BOM:543064 ) has established three distinct business verticals, each led by experienced industry leaders, enhancing operational ownership and accountability.
-
The company received US regulatory approval for a late-stage molecule in the respiratory inflammatory segment, marking a significant milestone for its CDMO platform.
-
Cohance Lifesciences Ltd ( BOM:543064 ) has strengthened its leadership and technical talent base, adding senior professionals from top global and Indian pharma companies.
-
The company has a strong pipeline with nine phase 3 molecules, with four expected to transition into commercial supply over the next 12 to 18 months.
-
Cohance Lifesciences Ltd ( BOM:543064 ) has completed four major customer audits successfully, indicating strong quality and delivery standards.
Negative Points
-
The company experienced an 8% year-on-year decline in revenue for the quarter, primarily due to shipment delays at its CDMO and FDF sites.
-
There were challenges with restocking key molecules and delayed reloads of a few phase 3 molecules, affecting overall performance.
-
The Nachara plant faced a shutdown awaiting audit clearance, impacting order shipments and production cycles.
-
The biotech funding environment has been challenging, affecting NJ Bio's project shipments and timelines.
-
Cohance Lifesciences Ltd ( BOM:543064 ) revised its FY26 guidance to be broadly flat compared to FY25, citing ongoing challenges and destocking issues.
Q & A Highlights
-
Warning! GuruFocus has detected 4 Warning Signs with BOM:543064.
-
Is BOM:543064 fairly valued? Test your thesis with our free DCF calculator.
Q: Can you explain the value chain of the ADC business and how Cohance participates in it? A: Jan, CEO of Pharma CDMO, explained that ADCs consist of monoclonal antibodies, a linker, and a payload. Cohance offers payloads and starting materials for payloads, fully back-integrated in India, providing supply security. They also offer R&D and manufacturing services, enabling innovators to develop life-saving drugs.
Q: How does Cohance's scientific capabilities translate to its earnings or revenue growth, especially in ADCs? A: The company is involved in two out of the 12 ADCs approved globally. Pharmaceutical companies build stock and de-stock to manage launches, which affects Cohance's delivery as a starting material provider. The pipeline of customer projects is a more critical indicator of future growth.
Q: When can we expect an inflection point for niche technologies in the CDMO business? A: Jan indicated that while they are participating in more drug developments, the exact timing of commercial success is uncertain. However, their capabilities, especially in India, position them well for future commercial drug participation.
Q: What is the confidence level in the H2 and FY27 guidance, given past discrepancies? A: Vivek Sharma, Executive Chairman, stated that the guidance is based on customer interactions, RFPs, and pipeline visibility. They are confident in the second half of the year and expect positive traction across different business segments.
Q: How should we view the ramp-up of four molecules expected to go commercial in the next 12-18 months? A: The ramp-up depends on the success of the originator's launch. Cohance is optimistic about the launches, especially for small molecule portfolios, but exact quantities and timing are uncertain.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
